JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
about
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FOptimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.Ruxolitinib: a review of its use in patients with myelofibrosis.A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.Research and progress on ClC‑2 (Review).Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemiaJAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growthLentiginoses in polycythemia vera patient: Is there a role for JAK2 (V617F) mutation?Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotypeCoexistence of follicular lymphoma and an unclassifiable myeloproliferative neoplasm in a treatment-naïve patient: A case reportClonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series.Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.Lessons and Implications from Genome-Wide Association Studies (GWAS) Findings of Blood Cell Phenotypes.Emerging immunosuppressive drugs in myelodysplastic syndromes.Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.Upregulation of the large conductance voltage- and Ca2+-activated K+ channels by Janus kinase 2.Determinants of the extent and duration of STAT3 signaling.Methylation of SOCS3 in Myeloproliferative Neoplasms and Secondary Erythrocytosis/Thrombocythemia.Downregulation of KCNQ4 by Janus kinase 2.Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR.Up-regulation of Kv1.3 channels by janus kinase 2.Down-regulation of the epithelial Na⁺ channel ENaC by Janus kinase 2.Down-regulation of the myoinositol transporter SMIT by JAK2.Downregulation of the creatine transporter SLC6A8 by JAK2.
P2860
Q26795666-35B62B86-BFCB-4D4F-8F40-88D4CA47D1FBQ33411763-F153CC4D-498E-4C45-9194-C700EC6E7ACCQ33419865-BF786743-1AAC-417D-93D9-D6B53E938A76Q33420095-70A7E51B-8D9D-495F-9551-B86BB388E0C9Q33828111-E218AF94-A57F-40E4-BE28-EF05189085D3Q35217865-536DD6CE-D47B-4E05-92FC-827967816596Q35861885-51852D32-FB84-4D32-9D6D-724C190B0F11Q36093112-247E8650-0E1E-492E-8562-795EEBAB77F7Q36286847-DCBA2E2F-FBA8-4AD6-8ED0-E4752A0531CFQ36524740-A01358C2-BA1D-4672-B060-67360B9EA702Q36693223-A056C771-8EFA-424F-A81B-355B521CE91FQ37638779-7D551F83-B354-44EB-8BCB-425452980147Q37689829-4DFB7E2E-1D6C-4AEB-871B-093B307A70A0Q38060835-AAD5052E-1361-471D-980F-702D49344CDAQ38248429-DC6D3096-32EE-4E3E-9732-E74D8DAB6853Q39008720-0B1DC94A-AFC4-4038-A964-3F9D0295F9E7Q41390271-8F5D2A51-FA95-4261-9FA1-EDF87D71182EQ42970256-6EF9A9A4-647E-44DD-8F4D-64E0499E512DQ45817343-F7C541C7-E962-4D37-A00E-4F31CE192D52Q46886345-B386AF36-83CD-42F3-B8E7-85CEEE06514BQ48278379-F2062CF0-0276-4504-B71E-7C9CF78824DEQ48586068-2C6126BC-A697-4BBC-A962-47EA5DF4048BQ48607961-2E89DD3B-A754-462B-9A88-CE561D189F7CQ48635036-19AE7A53-9C62-49CC-A0C6-BFB357342C37Q48653545-3C987F9C-FD5E-40DA-BBCB-AAD53FFA1A69
P2860
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
JAK2 V617F and beyond: role of ...... myeloproliferative neoplasms.
@en
JAK2 V617F and beyond: role of ...... myeloproliferative neoplasms.
@nl
type
label
JAK2 V617F and beyond: role of ...... myeloproliferative neoplasms.
@en
JAK2 V617F and beyond: role of ...... myeloproliferative neoplasms.
@nl
prefLabel
JAK2 V617F and beyond: role of ...... myeloproliferative neoplasms.
@en
JAK2 V617F and beyond: role of ...... myeloproliferative neoplasms.
@nl
P2860
P356
P1476
JAK2 V617F and beyond: role of ...... myeloproliferative neoplasms.
@en
P2093
Jason Gotlib
Stephen T Oh
P2860
P304
P356
10.1586/EHM.10.28
P577
2010-06-01T00:00:00Z